Vagifem

Atrophic Vaginitis, Low Testosterone, Hypogonadism + 27 more

Treatment

5 FDA approvals

20 Active Studies for Vagifem

What is Vagifem

Estradiol

The Generic name of this drug

Treatment Summary

Estradiol is a hormone naturally produced in females. It is used in hormone therapy to treat conditions related to low estrogen levels, such as hot flashes and vulvovaginal atrophy. It is available in many forms, including tablets, injections, vaginal rings, patches, sprays, gels, and creams. To increase its effectiveness when taken orally or through injection, estradiol is often combined with a pro-drug ester. Ethinyl estradiol is a synthetic form of estradiol that is more bioavailable and resistant to metabolism, making it the most common form used in combination oral contraceptive pills (

Estraderm

is the brand name

image of different drug pills on a surface

Vagifem Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Estraderm

Estradiol

1986

373

Approved as Treatment by the FDA

Estradiol, also known as Estraderm, is approved by the FDA for 5 uses like Hormonal Contraception and Breast Cancer .

Hormonal Contraception

Used to treat Hormonal Contraception therapy in combination with Levonorgestrel

Breast Cancer

Birth Control

Used to treat Contraception in combination with Levonorgestrel

Palliative Treatment

Breast Cancer

Effectiveness

How Vagifem Affects Patients

Estradiol is used to help relieve hot flashes, vaginal dryness, and pain during sex. It also helps increase bone density and can improve the levels of certain proteins in the liver. It can make blood clot more easily, which can increase the risk for heart disease, blood clots in veins, and stroke. Estradiol can also cause an increase in sodium retention and blood pressure.

How Vagifem works in the body

Estrogen is a hormone found in many parts of the body, like the breast, skin, and brain. In women of reproductive age, the majority of estrogen is made by the ovaries. After menopause, the main source of estrogen is the adrenal glands, which produce androstenedione and then turn it into estrone in other tissues. Estrogen works by binding to two types of receptors, ERα and ERβ, and GPER which helps it take effect quickly. When the receptor binds to estrogen, it travels to the nucleus of the cell and triggers gene transcription. This creates proteins which cause the effects of estrogen

When to interrupt dosage

The measure of Vagifem is founded upon the identified ailment, including Premature Menopause, Pharmaceutical Preparations and Postmenopause. The measure of dosage fluctuates as per the approach of delivery delineated in the table beneath.

Condition

Dosage

Administration

Hot flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Hormone Replacement Therapy

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

estradiol

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

female castration

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Postmenopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Prostate Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Breast

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Palliative Treatment

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Breast Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Hot Flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Vasomotor System

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Pharmaceutical Preparations

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Amenorrhea

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Premature Menopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Atrophic

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Balanitis Xerotica Obliterans

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Therapeutic procedure

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Hypogonadism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Osteoporosis

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

hypoestrogenism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Warnings

Vagifem has eighteen known contraindications and should be avoided for those experiencing the conditions given in the following table.

Vagifem Contraindications

Condition

Risk Level

Notes

Breast

Do Not Combine

Angioedema

Do Not Combine

Venous Thrombosis

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Liver Dysfunction

Do Not Combine

Breast

Do Not Combine

suspected pregnancy

Do Not Combine

Breast Cancer

Do Not Combine

Pulmonary Embolism

Do Not Combine

Angioedema

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Thromboembolism

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Pulmonary Embolism

Do Not Combine

Thromboembolism

Do Not Combine

Thrombophilia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Estradiol may interact with Pulse Frequency

There are 20 known major drug interactions with Vagifem.

Common Vagifem Drug Interactions

Drug Name

Risk Level

Description

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Estradiol.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Estradiol.

Anastrozole

Major

The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Estradiol.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Estradiol.

Vagifem Toxicity & Overdose Risk

Studies have found that taking estradiol for 90 days in rats had no adverse effects at doses of 0.003 mg/kg/day. The lowest toxic dose for ethinyl estradiol is 21 mg/kg/21D for women. An overdose of estradiol may cause nausea, vomiting, abdominal pain, breast tenderness, blood clots, and vaginal bleeding. If you suspect an overdose, it is recommended to stop taking the drug and get supportive care.

image of a doctor in a lab doing drug, clinical research

Vagifem Novel Uses: Which Conditions Have a Clinical Trial Featuring Vagifem?

867 ongoing studies are assessing the potential of Vagifem to alleviate Osteoporosis, absent menses for the preceding 6 months, and Urogenital Atrophy.

Condition

Clinical Trials

Trial Phases

Hysterectomy

4 Actively Recruiting

Phase 3, Not Applicable

Breast Cancer

18 Actively Recruiting

Phase 2, Phase 1, Not Applicable

estradiol

0 Actively Recruiting

Birth Control

20 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Postmenopause

6 Actively Recruiting

Phase 2, Not Applicable

Metastatic Breast Cancer

1 Actively Recruiting

Phase 1, Phase 2

Osteoporosis, Postmenopausal

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

moderate to severe symptoms

0 Actively Recruiting

Balanitis Xerotica Obliterans

0 Actively Recruiting

Amenorrhea

1 Actively Recruiting

Phase 2

Osteoporosis

28 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Prostate Cancer

72 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1

Breast

0 Actively Recruiting

Urogenital atrophy

0 Actively Recruiting

Low Testosterone

4 Actively Recruiting

Phase 4, Phase 2, Phase 1

Vasomotor System

0 Actively Recruiting

Atrophic Vaginitis

2 Actively Recruiting

Not Applicable, Phase 4

Hot flashes

21 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

Hormone Replacement Therapy

0 Actively Recruiting

Vagifem Reviews: What are patients saying about Vagifem?

4.3

Patient Review

5/16/2022

Vagifem for Postmenopausal Urethral Atrophy

As someone who has gone through menopause, I've found this treatment to be very effective for my bladder problems and dry vagina. I haven't experienced any negative side effects, though there is the occasional thrush infection which may be caused by the applicator. Overall, this has worked well for me.

3.7

Patient Review

5/11/2022

Vagifem for Wasting of Tissues of the Vulva

I've gained nine pounds, my breasts are larger and tender, my hair is falling out more quickly, I feel breathless and get mild headaches. While the moisturizing effect seems to have decreased, I do feel more comfortable deep inside and no longer feel like I have a UTI brewing all the time.

3

Patient Review

8/9/2022

Vagifem for Postmenopausal Urethral Atrophy

I initially had no issues with this medication, but after about a month I started to experience really unpleasant side effects like bloating, leg cramps, and hair loss. I'm hoping to speak to my doctor soon about discontinuing use.

3

Patient Review

11/6/2022

Vagifem for Vaginal Inflammation due to Loss of Hormone Stimulation

I did not do my research on this medication before taking it, and I regret that now. I can't say for certain whether or not Vagifem is causing my problems, but it's certainly possible. I've been experiencing extreme bloating and pelvic pain which has made daily life very difficult. Additionally, I'm constantly feeling the need to urinate. The one side effect that concerns me most after reading these reviews is hair loss. I have already lost 50% of my hair, and the texture has changed for the worse. As of now, I will be stopping use of this medication."

2.7

Patient Review

4/29/2022

Vagifem for Vaginal Inflammation due to Loss of Hormone Stimulation

I used this for five months to try and alleviate vaginal atrophy, but it only made the burning and stinging sensations worse. It also seemed to make my slight vaginal prolapse much worse. On top of all that, I got the worst thrush ever. So, on balance, I think I would have been better off without it.

2.7

Patient Review

5/5/2022

Vagifem for Postmenopausal Urethral Atrophy

I developed a really bad itch and discharge after using this for about eight days. It was like a yeast infection, so I stopped taking it immediately.

2.3

Patient Review

4/20/2022

Vagifem for Wasting of Tissues of the Vulva

The new Vagirux applicator is too shallow and the tablet falls out constantly.

1

Patient Review

3/14/2022

Vagifem for Marked Inflammation of Urethra, the Canal that leads From the Bladder

I've only been using this medication for four days, and I woke up this morning in excruciating pain. I'm continuing to take it as directed because I need a smear test, but the pain is unbearable. I don't know how I'm supposed to make it through 10 more days of this.

1

Patient Review

10/11/2022

Vagifem for Vaginal Inflammation due to Loss of Hormone Stimulation

The burning was unbearable and I felt like I had to constantly go to the bathroom. The pressure in my bladder was really intense.

1

Patient Review

2/25/2022

Vagifem for Vaginal Inflammation due to Loss of Hormone Stimulation

I have Ehlers-Danlos Syndrome and this medication made me very sick.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vagifem

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the risks of taking Vagifem?

"Vagifem® users most often reported experiencing headache, breast pain, irregular vaginal bleeding or spotting, stomach/abdominal cramps, bloating, nausea and vomiting, hair loss, fluid retention, and vaginal yeast infection."

Answered by AI

How quickly will Vagifem work?

"A study found that the drug Vagifem 10 mcg helped to reduce symptoms associated with vaginal atrophy in most women after 12 weeks of treatment, though some women reported seeing improvements as early as 8 weeks into treatment."

Answered by AI

What does Vagifem do for a woman?

"This medication is used to help reduce vaginal symptoms of menopause in women. These symptoms are caused by the body making less estrogen and can include vaginal dryness, burning, and itching."

Answered by AI

How long should you stay on Vagifem?

"It is currently recommended to continue using local estrogen therapy for as long as it is needed for symptom control. A study that looked back at data from over 13,000 women showed that, in the real world, local estrogen therapy is typically used for around 12 months."

Answered by AI

Clinical Trials for Vagifem

Image of Translational Physiology Laboratory within the Food Science Clinical Research Laboratory in Fort Collins, United States.

Mitoquinone for Postmenopausal Brain Health

18+
Female
Fort Collins, CO

The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are: Does MitoQ improve cerebrovascular function in postmenopausal women? If so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries? Researchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function. Participants will: Take MitoQ (20 mg/day) or a placebo every day for 3 months Visit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point Keep track of symptoms and events during their treatment period to report to the study team

Waitlist Available
Dietary Supplement

Translational Physiology Laboratory within the Food Science Clinical Research Laboratory

Image of M D Anderson Cancer Center in Houston, United States.

Decision Support Tool for Prostate Cancer

18+
Male
Houston, TX

This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.

Waitlist Available
Has No Placebo

M D Anderson Cancer Center

Debanjan Pain

Have you considered Vagifem clinical trials?

We made a collection of clinical trials featuring Vagifem, we think they might fit your search criteria.
Go to Trials
Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Inova Schar Cancer Institute in Fairfax, United States.

Acupuncture for Prostate Cancer

18+
Male
Fairfax, VA

Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.

Recruiting
Has No Placebo

Inova Schar Cancer Institute

Jeanny Aragon-Ching, MD

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Have you considered Vagifem clinical trials?

We made a collection of clinical trials featuring Vagifem, we think they might fit your search criteria.
Go to Trials
Image of University of Michigan Comprehensive Cancer Center in Ann Arbor, United States.

Self-Monitoring Platform for Cancer

18+
All Sexes
Ann Arbor, MI

This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.

Recruiting
Has No Placebo

University of Michigan Comprehensive Cancer Center

Yun Jiang

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Image of Mayo Clinic in Florida in Jacksonville, United States.

In-Home Treatment for Cancer

18+
All Sexes
Jacksonville, FL

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.

Phase 2
Recruiting

Mayo Clinic in Florida

Roxana S. Dronca, MD

Image of Washington University School of Medicine in St Louis, United States.

Supplemental Imaging for Breast Cancer

25 - 55
Female
St Louis, MO

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Tabassum Ahmad, M.D.

Have you considered Vagifem clinical trials?

We made a collection of clinical trials featuring Vagifem, we think they might fit your search criteria.
Go to Trials